DBV Technologies FY2025 net loss $147M; cash runway into Q2 2027; BLA on track H1 2026

DBV Technologies S.A.

Net loss of $147M for FY2025, compared to $113.9M in FY2024; diluted EPS -$1.05.
Operating income $5.6M, up from $4.2M; R&D expenses rose to $116.7M due to pre-commercial inventory and clinical costs.
Cash and equivalents $194.2M as of Dec 31, 2025; additional $94M received Jan 2026; funding into Q2 2027.
BLA submission for VIASKIN Peanut Patch in children aged 4-7 years anticipated H1 2026; for toddlers 1-3 years H2 2026.
Appointed Kevin Trapp as CCO and James Briggs as CHRO; Philina Lee nominated to Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

DBV Technologies S.A. reported the fiscal year ended December 31, 2025 results: net income $147.0 million, EPS $1.05.

Period: the fiscal year ended December 31, 2025
Net income: $147.0 million
EPS: $1.05
Result: reported results

Exact text from the filing

Net loss was $147.0 million for the year ended December 31, 2025, compared to $113.9 million for the year ended December 31, 2024. Net loss per share (based on the weighted average number of shares outstanding over the period) was $1.05 and $1.17 for the year ended December 31, 2025 and 2024, respectively.

View on SEC.gov

1435 earnings releases filed in the last 30 days. Browse all earnings releases →

DBV Technologies S.A. filing history →

Source: SEC EDGAR

accession 0001193125-26-126671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.